TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34755881

Group type: EXPERIMENTAL
Intervention: Sleep macrostructure measurements
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Spindle features during first sleep cycle
Number of subjects: 91

Group type: COMPARATOR
Intervention: Comparison of spindle features by sex
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Second sleep cycle measurements
Number of subjects: 91
Study: 34756569

Group type: EXPERIMENTAL
Intervention: Dynamic artificial intelligence approach using Bayesian joint models
Number of subjects: 13608
Study: 34756674

Group type: EXPERIMENTAL
Intervention: High density lipoprotein (HDL) particle concentration in AH
Number of subjects: 365

Group type: COMPARATOR
Intervention: High density lipoprotein (HDL) particle concentration in heavy drinkers
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: HDL particle concentration in AH patients
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: HDL particle concentration < 3.5 μmol/L and total cholesterol ≤ 96 mg/dL in AH patients
Number of subjects: 365
Study: 34756943

Group type: EXPERIMENTAL
Intervention: Antibiotic treatment
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: HADS scores
Number of subjects: 368

Group type: COMPARATOR
Intervention: Initial anxiety or depression status
Number of subjects: 368
Study: 34757189

Group type: EXPERIMENTAL
Intervention: Anticoagulation interrupted
Number of subjects: 1795

Group type: EXPERIMENTAL
Intervention: Anticoagulation continued
Number of subjects: 1795

Group type: EXPERIMENTAL
Intervention: No anticoagulation
Number of subjects: 1795

Group type: COMPARATOR
Intervention: Any anticoagulation strategy
Number of subjects: 1795
Study: 34757194

Group type: EXPERIMENTAL
Intervention: UV-oHSV2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: UV-oHSV2-stimulated NK92 cells with anti-NKG2A and anti-HLA-E treatment
Number of subjects: 0
Study: 34757489

Group type: EXPERIMENTAL
Intervention: PIPAC-OX (oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy)
Number of subjects: 20
Study: 34757602

Group type: EXPERIMENTAL
Intervention: Pirfenidone tablets
Number of subjects: 288

Group type: COMPARATOR
Intervention: Pirfenidone capsules
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Pirfenidone (tablets and substitution)
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Pirfenidone (overall)
Number of subjects: 288
Study: 34757829

Group type: EXPERIMENTAL
Intervention: Advanced obesity treatment
Number of subjects: 0
Study: 34757973

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART) adherence measured electronically in a subcohort of 324 clients.
Number of subjects: 14632

Group type: EXPERIMENTAL
Intervention: Risk of running out of ART after national lockdown.
Number of subjects: 14632

Group type: EXPERIMENTAL
Intervention: Viral suppression in HIV clients.
Number of subjects: 14632
Study: 34758807

Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood glucose (SMBG) using a novel blood glucose monitoring (BGM) system
Number of subjects: 359
Study: 34758808

Group type: EXPERIMENTAL
Intervention: High intensity interval exercise training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Moderate intensity continuous exercise training
Number of subjects: 0
Study: 34758857

Group type: COMPARATOR
Intervention: Ankle exoskeleton during inclined walking
Number of subjects: 11

Group type: COMPARATOR
Intervention: Ankle exoskeleton for stair climbing
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Device usability metrics for CP cohort
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Device usability metrics for unimpaired cohort
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: System Usability Scale score for exoskeleton
Number of subjects: 11
Study: 34758861

Group type: EXPERIMENTAL
Intervention: Mature thoracoscopic-laparoscopic oesophagectomy
Number of subjects: 214

Group type: COMPARATOR
Intervention: Open oesophagectomy
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Thoracoscopic-laparoscopic oesophagectomy
Number of subjects: 214
Study: 34758881

Group type: EXPERIMENTAL
Intervention: mHealth platform for electronic PRO collection
Number of subjects: 101
Study: 34758995

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (loading dose of 0.6 µg/kg in 10 min followed by continuous infusion at 0.4 µg/kg/hour until dural closure)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal saline (identical volume to dexmedetomidine group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 0
Study: 34759712

Group type: EXPERIMENTAL
Intervention: High body mass index (BMI)
Number of subjects: 768

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 768
Study: 34754421

Group type: EXPERIMENTAL
Intervention: Continuous monitoring of postoperative vital signs abnormalities
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuous monitoring of postoperative vital signs
Number of subjects: 0
Study: 34760950

Group type: EXPERIMENTAL
Intervention: Team-Based Care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 0
Study: 34760951

Group type: EXPERIMENTAL
Intervention: External Counterpulsation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 34761160

Group type: EXPERIMENTAL
Intervention: 24-hour urine collection
Number of subjects: 153

Group type: COMPARATOR
Intervention: 24-hour estimated excretion from spot urine sample
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Enhanced biomarker models
Number of subjects: 153
Study: 34761647

Group type: EXPERIMENTAL
Intervention: EDTA tubes
Number of subjects: 3568

Group type: COMPARATOR
Intervention: Streck tubes
Number of subjects: 3568

Group type: EXPERIMENTAL
Intervention: Storage at -80 °C
Number of subjects: 3568

Group type: EXPERIMENTAL
Intervention: Gestational age
Number of subjects: 3568

Group type: EXPERIMENTAL
Intervention: Trisomy 21
Number of subjects: 3568

Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 3568

Group type: EXPERIMENTAL
Intervention: Male fetus
Number of subjects: 3568

Group type: EXPERIMENTAL
Intervention: Trisomy 18
Number of subjects: 3568

Group type: EXPERIMENTAL
Intervention: Turners syndrome
Number of subjects: 3568

Group type: EXPERIMENTAL
Intervention: Triploidy
Number of subjects: 3568
Study: 34761665

Group type: EXPERIMENTAL
Intervention: Intravascular lithotripsy (IVL)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Rotational atherectomy (RA)
Number of subjects: 180
Study: 34761878

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoimmunotherapy (pembrolizumab combined with chemotherapy)
Number of subjects: 1
Study: 34762062

Group type: EXPERIMENTAL
Intervention: Global COVID-19 Registry Database
Number of subjects: 64114

Group type: EXPERIMENTAL
Intervention: Agile project management approach
Number of subjects: 64114

Group type: EXPERIMENTAL
Intervention: Data collection from 306 sites
Number of subjects: 64114
Study: 34762093

Group type: EXPERIMENTAL
Intervention: ATRA and arsenic trioxide regimen (chemotherapy-free) for standard-risk APL
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: ATRA and arsenic trioxide regimen with 4 doses of idarubicin during induction therapy for high-risk APL
Number of subjects: 154

Group type: COMPARATOR
Intervention: Historical control group from AAML0631 study
Number of subjects: 154
Study: 34762513

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients with aortic stenosis and mitral valve insufficiency
Number of subjects: 0
Study: 34762658

Group type: EXPERIMENTAL
Intervention: Adenomas
Number of subjects: 767

Group type: EXPERIMENTAL
Intervention: Adenomas larger than 2 cm
Number of subjects: 767

Group type: EXPERIMENTAL
Intervention: Right-sided adenomas
Number of subjects: 767

Group type: COMPARATOR
Intervention: Serrated lesions
Number of subjects: 767
Study: 34762776

Group type: EXPERIMENTAL
Intervention: Dysosmia
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normosmia
Number of subjects: 60
Study: 34762863

Group type: EXPERIMENTAL
Intervention: Wireless pregnancy monitor
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Wireless pregnancy monitor and intrauterine pressure catheter
Number of subjects: 118

Group type: COMPARATOR
Intervention: Tocodynamometry
Number of subjects: 118
Study: 34763085

Group type: EXPERIMENTAL
Intervention: eladocagene exuparvovec
Number of subjects: 26
Study: 34763195

Group type: EXPERIMENTAL
Intervention: Osimertinib 80 mg daily
Number of subjects: 22
Study: 34763234

Group type: EXPERIMENTAL
Intervention: High adherence group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Establishing exercise habits
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Consulting a physical therapist during hospitalization
Number of subjects: 0
Study: 34763665

Group type: EXPERIMENTAL
Intervention: D-chiro-inositol (DCI) 600 mg, two times per day for 30 days
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: D-chiro-inositol (DCI)
Number of subjects: 10
Study: 34763776

Group type: EXPERIMENTAL
Intervention: Molecular imaging with phosphatidylserine microbubbles (MB)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 0.10 or 0.15 mL of MB
Number of subjects: 17
Study: 34763939

Group type: EXPERIMENTAL
Intervention: Objective LLL assessment based on limb volume change (LVC) using circumferential limb measurements
Number of subjects: 150
Study: 34764171

Group type: EXPERIMENTAL
Intervention: General anaesthesia and transversus thoracis muscle plane block (TTPB)
Number of subjects: 42

Group type: COMPARATOR
Intervention: General anaesthesia only
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: General anaesthesia and TTPB
Number of subjects: 42
Study: 34764932

Group type: EXPERIMENTAL
Intervention: Fampridine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 34764938

Group type: EXPERIMENTAL
Intervention: Fat mass index (FMI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Body mass index (BMI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Waist circumference (WC)
Number of subjects: 0
Study: 34765102

Group type: EXPERIMENTAL
Intervention: ECG247 Smart Heart Sensor
Number of subjects: 150

Group type: COMPARATOR
Intervention: Holter monitor
Number of subjects: 150
Study: 34765108

Group type: EXPERIMENTAL
Intervention: TACE + Bevacizumab (B)
Number of subjects: 0

Group type: COMPARATOR
Intervention: TACE alone
Number of subjects: 0
Study: 34765307

Group type: EXPERIMENTAL
Intervention: Camrelizumab 200 mg every 2 weeks until disease progression or unacceptable toxicity
Number of subjects: 6
Study: 34765319

Group type: EXPERIMENTAL
Intervention: mAdAPT-001 (AdAPT-001) injected intratumorally
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: mAdAPT-001 (AdAPT-001) injected intravenously
Number of subjects: 50
Study: 34765593

Group type: EXPERIMENTAL
Intervention: Kinect-Based Constraint-Induced Therapy Program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 34766208

Group type: EXPERIMENTAL
Intervention: Very-low-energy, viscous placebo breakfast (PLA)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Whole-food breakfast (FOOD)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Water-only breakfast (WAT)
Number of subjects: 14
Study: 34766217

Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin-based chemotherapy (including regimens other than BR)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin-based chemotherapy
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin-based chemotherapy with subsequent hematopoietic stem cell transplantation (HSCT)
Number of subjects: 40
Study: 34766330

Group type: EXPERIMENTAL
Intervention: Multidisciplinary rehabilitation (inpatient setting)
Number of subjects: 5351

Group type: COMPARATOR
Intervention: Supported discharge and multidisciplinary home rehabilitation
Number of subjects: 5351
Study: 34766576

Group type: EXPERIMENTAL
Intervention: Self-reported vaccination rates for hepatitis A virus (HAV)
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Self-reported vaccination rates for hepatitis B virus (HBV)
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Self-reported vaccination rates for seasonal influenza
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Self-reported vaccination rates for pneumococcus
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Knowledge of vaccination recommendations
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Negative IgG anti-HAV antibody status
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Negative IgG HBV surface antibody status
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Association with newspaper subscription
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Association with physician recommendation for vaccination
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Association with use of anti-tumor necrosis factor agents
Number of subjects: 287
Study: 34767089

Group type: EXPERIMENTAL
Intervention: Patient navigation services
Number of subjects: 7
Study: 34767131

Group type: EXPERIMENTAL
Intervention: Trimetazidine
Number of subjects: 173
Study: 34767652

Group type: EXPERIMENTAL
Intervention: Filgrastim at 5 μg/kg in morbidly obese patients
Number of subjects: 30

Group type: COMPARATOR
Intervention: Filgrastim at 5 μg/kg in non-obese patients
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Filgrastim dosing based on actual body weight
Number of subjects: 30
Study: 34767753

Group type: EXPERIMENTAL
Intervention: CRKP infection in China (n=246)
Number of subjects: 991

Group type: EXPERIMENTAL
Intervention: CRKP infection in South America (n=109)
Number of subjects: 991

Group type: EXPERIMENTAL
Intervention: CRKP infection in the USA (n=130)
Number of subjects: 991

Group type: COMPARATOR
Intervention: CRKP infection in China
Number of subjects: 991

Group type: COMPARATOR
Intervention: CRKP infection in the USA
Number of subjects: 991

Group type: COMPARATOR
Intervention: CRKP infection in South America
Number of subjects: 991

Group type: COMPARATOR
Intervention: CRKP infection in South America vs China
Number of subjects: 991

Group type: COMPARATOR
Intervention: CRKP infection in USA vs China
Number of subjects: 991

Group type: COMPARATOR
Intervention: CRKP infection in USA vs South America
Number of subjects: 991
Study: 34767759

Group type: EXPERIMENTAL
Intervention: mRNA-1273 COVID-19 vaccine (100 μg in 0.5 mL intramuscularly, 2 doses, 28 days apart)
Number of subjects: 791
Study: 34767765

Group type: COMPARATOR
Intervention: Quadrivalent HPV vaccine (HPV4) or nonavalent HPV vaccine (HPV9) administered in three doses over 6 months (on day 1, at month 2, and at month 6).
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: HPV9 in female participants aged 16-26 years
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: HPV4 in male participants aged 16-26 years
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: HPV9 in female participants aged 9-15 years
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: HPV4 in female participants aged 9-15 years
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: HPV4 in male participants aged 9-15 years
Number of subjects: 453
Study: 34767785

Group type: EXPERIMENTAL
Intervention: Spermidine (Spd) supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Loss of SMOX
Number of subjects: 0
Study: 34767825

Group type: EXPERIMENTAL
Intervention: Forced expiratory volume in 3 s (FEV3)
Number of subjects: 832

Group type: EXPERIMENTAL
Intervention: Forced expiratory volume in 6 s (FEV6)
Number of subjects: 832
Study: 34767985

Group type: EXPERIMENTAL
Intervention: Medtronic ICD lead monitoring alerts
Number of subjects: 4942

Group type: COMPARATOR
Intervention: Pacing impedance threshold alert
Number of subjects: 4942

Group type: EXPERIMENTAL
Intervention: Lead monitoring alerts
Number of subjects: 4942
Study: 34768160

Group type: EXPERIMENTAL
Intervention: Sarcopenia
Number of subjects: 570

Group type: EXPERIMENTAL
Intervention: Sarcopenic Obesity (SO)
Number of subjects: 570

Group type: COMPARATOR
Intervention: Obesity
Number of subjects: 570

Group type: EXPERIMENTAL
Intervention: Mini Nutritional Assessment (MNA) as a mediator
Number of subjects: 570
Study: 34768176

Group type: EXPERIMENTAL
Intervention: Piperacillin-tazobactam
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Meropenem
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Cefepime
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Fixed dose protocol with prolonged infusion
Number of subjects: 89
Study: 34768178

Group type: EXPERIMENTAL
Intervention: Fenfluramine (FFA)
Number of subjects: 732

Group type: COMPARATOR
Intervention: Standard-of-care (Control)
Number of subjects: 732
Study: 34768339

Group type: EXPERIMENTAL
Intervention: Acute encephalopathy group (10 patients)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (20 patients)
Number of subjects: 30
Study: 34768516

Group type: EXPERIMENTAL
Intervention: OviTex (reinforced tissue matrix)
Number of subjects: 92
Study: 34768571

Group type: EXPERIMENTAL
Intervention: CD14++CD16+ monocytes in peripheral blood (PB)
Number of subjects: 66
Study: 34768692

Group type: EXPERIMENTAL
Intervention: Biofeedback therapy (BFT) performed once or twice a week during the temporary stoma period
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (no biofeedback therapy)
Number of subjects: 44
Study: 34769657

Group type: EXPERIMENTAL
Intervention: Erosive reflux disease (ERD)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Eosinophilic esophagitis (EoE)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Schatzki ring (SR)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Normal esophagus
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: ERD and SR with UES insufficiency
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Esophageal motility disorders
Number of subjects: 58
Study: 34769680

Group type: EXPERIMENTAL
Intervention: Patient-Centered Medical Home (PCMH)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Change strategies employed to implement PCMH innovations
Number of subjects: 22
Study: 34771451

Group type: EXPERIMENTAL
Intervention: APVO436
Number of subjects: 4
Study: 34771728

Group type: EXPERIMENTAL
Intervention: Cisplatin and gemcitabine plus bevacizumab
Number of subjects: 0
Study: 34772318

Group type: EXPERIMENTAL
Intervention: Participatory ergonomics strategies used for 8 weeks; frequency of use >50% for 5 days a week.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Participatory ergonomics strategies; no specific control group mentioned.
Number of subjects: 0
Study: 34772347

Group type: EXPERIMENTAL
Intervention: Polymer-free sirolimus-eluting Nano plus stent
Number of subjects: 2481
Study: 34772362

Group type: EXPERIMENTAL
Intervention: Tricuspid valve surgery (TV group)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Mitral valve surgery (MV group)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Comparison between TV and MV groups
Number of subjects: 48
Study: 34772417

Group type: EXPERIMENTAL
Intervention: Presence of thin-cap fibroatheroma (TCFA) in culprit lesions
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: Residual syntax score (rSS) divided into three groups
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: ROC curve analysis
Number of subjects: 434
Study: 34772433

Group type: EXPERIMENTAL
Intervention: High-intensity Mediterranean diet intervention
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard-of-care arm
Number of subjects: 100
Study: 34772439

Group type: EXPERIMENTAL
Intervention: GD2.CAR T-cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PMN-MDSC
Number of subjects: 0
Study: 34772665

Group type: EXPERIMENTAL
Intervention: EYEMATE-SC sensor implantation
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: EYEMATE-SC sensor measurements
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: EYEMATE-SC sensor
Number of subjects: 24
Study: 34772746

Group type: EXPERIMENTAL
Intervention: Meditation programme (12 weekly sessions of 1.5 hours each)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Meditation programme
Number of subjects: 30
Study: 34772747

Group type: EXPERIMENTAL
Intervention: Resilient Caregivers intervention (seven manualised group sessions, 2.5 hours each)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 80
Study: 34772758

Group type: EXPERIMENTAL
Intervention: Tremelimumab (10 mg/kg) + MEDI3617 (200 mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Tremelimumab (10 mg/kg) + MEDI3617 (600 mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Tremelimumab + MEDI3617
Number of subjects: 15
Study: 34772767

Group type: EXPERIMENTAL
Intervention: Patients dissatisfied with care (scored 0 to 5 on a 0 to 10 scale)
Number of subjects: 1697

Group type: COMPARATOR
Intervention: Patients satisfied with care (scored 9 to 10 on a 0 to 10 scale)
Number of subjects: 1697
Study: 34773516

Group type: EXPERIMENTAL
Intervention: Cardiopulmonary resuscitation (CPR) attempt
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Sepsis-related organ failure assessment score > 9 before CA occurrence
Number of subjects: 186
Study: 34773596

Group type: EXPERIMENTAL
Intervention: fNIRS-guided rTMS treatment (n=20)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: MEP-guided rTMS treatment (n=16)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Sham group (n=15)
Number of subjects: 51
Study: 34774057

Group type: EXPERIMENTAL
Intervention: Stress Management and Resiliency Training Program for Residents (SMART-R)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SMART-R
Number of subjects: 0
Study: 34774099

Group type: EXPERIMENTAL
Intervention: Wen Xin granular
Number of subjects: 502

Group type: COMPARATOR
Intervention: Wen Xin granular placebo
Number of subjects: 502
Study: 34774107

Group type: EXPERIMENTAL
Intervention: UC-MSCs
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: UC-MSCs with IFNγ or IFNγ + TNFα
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: UC-MSCs with IFNγ
Number of subjects: 15
Study: 34774105

Group type: COMPARATOR
Intervention: Oculomotor tasks (Gap, Step, Overlap, Antisaccade)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Antisaccade task
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Correlation analysis with ADHD comorbidity index and executive functioning scales
Number of subjects: 82
Study: 34774184

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34774363

Group type: EXPERIMENTAL
Intervention: Persuasive messaging that invokes prosocial vaccination and social image concerns
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Persuasive messaging based on contemporary concerns (restricting personal freedom, economic security)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prosocial messaging
Number of subjects: 0